The Vital Role Of Start-Ups In Medtech Innovation
The MDR Threatens To Drive EU Start-ups To The US And The Outstanding EU MRA Is A Further Hurdle For Swiss Medtech Innovators
Focus On Switzerland – Part 4: The fragile nature of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.
You may also be interested in...
Shaped by Brexit, driven by COVID, squeezed by budgets and being engineered for the future, it seems that almost every element within UK health delivery and market access is undergoing change. How should the medtech industry prepare, and will there be implications beyond the UK?
The UK's medtech regulatory consultation has closed and the MHRA must now assess the views of stakeholders on the 465 questions designed to help shape the foundations of a future-proofed regulatory system. But time is tight, as speakers at the ABHI’s annual regulatory conference were at pains to stress.
The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.